ADVISORY, Aug. 07, 2017 --
What:
Tyme Technologies Inc. (Nasdaq:TYME), a clinical stage biotechnology company developing novel cancer therapeutics to address multiple tumor types, will visit the Nasdaq MarketSite in Times Square in celebration of their recent IPO.
On Facebook: https://www.facebook.com/tymetechnologies
On LinkedIn: https://www.linkedin.com/company-beta/11139295/
In honor of the occasion, Tyme Co-founders Steven Hoffman, CEO & Chief Science Officer, and Michael Demurjian, Chief Operating Officer, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Tuesday, August 8, 2017 – 9:15 a.m. to 9:30 a.m. ET
Tyme Technologies Inc. Media Contact:
James Heins/ICR
203-856-2121
[email protected]
Nasdaq MarketSite:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Tyme
Tyme Inc. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer. For more information, visit our website: www.tymeinc.com.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-


Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
OpenAI Explores Massive Funding Round at $750 Billion Valuation
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 



